Physician profile
Manish Singh
NPI 1982712063
$8,888.55
in general payments reported to CMS, 2019-2025
41 companies · $841 in 2025
The $841 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,576 · 2020: $1,573 · 2021: $1,092 · 2022: $840 · 2023: $1,365 · 2024: $1,603 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,808.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,017.72 | 2019-2021 | |
| Amgen INC. | $641.18 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $632.53 | 2019-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $456.70 | 2021-2025 | Vraylar, Botox, Qulipta |
| Collegium Pharmaceutical, INC. | $429.91 | 2022-2025 | Belbuca |
| Sk Life Science, INC. | $397.51 | 2021-2024 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $347.72 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $313.09 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $261.42 | 2021-2024 | Xarelto |
| Gilead Sciences, INC. | $245.00 | 2019-2025 | Epclusa |
| Acadia Pharmaceuticals INC | $244.82 | 2023 | Nuplazid |
| Depuy Synthes Sales INC. | $181.91 | 2021-2025 | Peak, Orthovisc, Monovisc |
| Kowa Pharmaceuticals America, INC. | $180.70 | 2022-2023 | Seglentis |
| Celgene Corporation | $164.23 | 2021 | |
| Alexion Pharmaceuticals, INC. | $149.03 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.